SI2744831T1 - TRANSFERIN-TUMSTATIN FUSION PROTEIN AND METHODS FOR THE MANUFACTURE AND USE OF LE-TEGA - Google Patents
TRANSFERIN-TUMSTATIN FUSION PROTEIN AND METHODS FOR THE MANUFACTURE AND USE OF LE-TEGA Download PDFInfo
- Publication number
- SI2744831T1 SI2744831T1 SI201231232T SI201231232T SI2744831T1 SI 2744831 T1 SI2744831 T1 SI 2744831T1 SI 201231232 T SI201231232 T SI 201231232T SI 201231232 T SI201231232 T SI 201231232T SI 2744831 T1 SI2744831 T1 SI 2744831T1
- Authority
- SI
- Slovenia
- Prior art keywords
- tumstatin
- recombinant protein
- nucleic acid
- recombinant
- transferrin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 7
- 108020001507 fusion proteins Proteins 0.000 title claims 2
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract 16
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract 16
- 102100033780 Collagen alpha-3(IV) chain Human genes 0.000 claims abstract 12
- 108010012374 type IV collagen alpha3 chain Proteins 0.000 claims abstract 12
- 102000004338 Transferrin Human genes 0.000 claims abstract 8
- 108090000901 Transferrin Proteins 0.000 claims abstract 8
- 239000012581 transferrin Substances 0.000 claims abstract 8
- 239000013612 plasmid Substances 0.000 claims abstract 3
- 102000004169 proteins and genes Human genes 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract 2
- 150000007523 nucleic acids Chemical group 0.000 claims 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 102100028187 ATP-binding cassette sub-family C member 6 Human genes 0.000 claims 1
- 208000005598 Angioid Streaks Diseases 0.000 claims 1
- 208000033825 Chorioretinal atrophy Diseases 0.000 claims 1
- 201000002563 Histoplasmosis Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 201000004613 Pseudoxanthoma elasticum Diseases 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000023558 pseudoxanthoma elasticum (inherited or acquired) Diseases 0.000 claims 1
- 230000001772 anti-angiogenic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161524508P | 2011-08-17 | 2011-08-17 | |
| EP12824616.2A EP2744831B1 (en) | 2011-08-17 | 2012-08-15 | Transferrin-tumstatin fusion protein and methods for producing and using the same |
| PCT/US2012/051013 WO2013025846A2 (en) | 2011-08-17 | 2012-08-15 | Transferrin-tumstatin fusion protein and methods for producing and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2744831T1 true SI2744831T1 (en) | 2018-04-30 |
Family
ID=47715692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231232T SI2744831T1 (en) | 2011-08-17 | 2012-08-15 | TRANSFERIN-TUMSTATIN FUSION PROTEIN AND METHODS FOR THE MANUFACTURE AND USE OF LE-TEGA |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9290562B2 (enExample) |
| EP (1) | EP2744831B1 (enExample) |
| JP (1) | JP6073888B2 (enExample) |
| CN (2) | CN110105453A (enExample) |
| AU (1) | AU2012296588B2 (enExample) |
| BR (1) | BR112014008680A2 (enExample) |
| CA (1) | CA2849015C (enExample) |
| DK (1) | DK2744831T3 (enExample) |
| ES (1) | ES2659161T3 (enExample) |
| NO (1) | NO2820418T3 (enExample) |
| PL (1) | PL2744831T3 (enExample) |
| PT (1) | PT2744831T (enExample) |
| SI (1) | SI2744831T1 (enExample) |
| TR (1) | TR201802686T4 (enExample) |
| WO (1) | WO2013025846A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2686968T3 (es) * | 2013-05-06 | 2018-10-23 | China Pharmaceutical University | Proteínas de fusión bifuncionales para inhibir la angiogénesis en el microambiente tumoral y para activar las respuestas inmunitarias adaptativas y los genes y usos de las mismas |
| JP2016522249A (ja) * | 2013-06-20 | 2016-07-28 | ノバルティス アーゲー | 脈絡膜血管新生の治療におけるｖｅｇｆアンタゴニストの使用 |
| US11058750B2 (en) | 2015-12-03 | 2021-07-13 | Mor Research Applications Ltd. | Compositions and methods for treatment of ocular diseases |
| KR101818151B1 (ko) | 2016-03-25 | 2018-01-16 | 한국과학기술원 | 트렌스페린을 포함하는 허혈성망막병증 예방 및 치료용 조성물 |
| CN109053899B (zh) * | 2017-12-22 | 2021-11-16 | 湖南远泰生物技术有限公司 | 一种含人转铁蛋白抗原表位序列的嵌合体抗原受体 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5672683A (en) | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US20050192242A1 (en) | 1995-10-11 | 2005-09-01 | Neal Zane C. | Therapeutic fusion protein transgenes |
| IL140239A0 (en) * | 1998-06-17 | 2002-02-10 | Beth Israel Hospital | Anti-angiogenic proteins and methods of use thereof |
| JP2003517847A (ja) | 1999-12-23 | 2003-06-03 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | トランスフェリンポリヌクレオチド、ポリペプチド、および抗体 |
| CN1628126A (zh) | 2001-08-30 | 2005-06-15 | 比奥雷克西斯药物公司 | 经修饰的运铁蛋白融合蛋白 |
| US8129504B2 (en) * | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
| CA2841097A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
| US20060122374A1 (en) * | 2002-02-07 | 2006-06-08 | Peter Mertins | Albumin-fused anti-angiogenesis peptides |
| WO2005034877A2 (en) | 2003-10-10 | 2005-04-21 | University Of Southern California | G-csf transferrin fusion proteins |
| JP2007526322A (ja) * | 2004-03-02 | 2007-09-13 | マサチューセッツ インスティテュート オブ テクノロジー | ナノセル薬物送達系 |
| US20080207502A1 (en) | 2004-10-14 | 2008-08-28 | Sopherion Therapeutics, Inc. | Anti-Angiogenic Peptides and Methods of Use Thereof |
| WO2006049983A2 (en) | 2004-10-27 | 2006-05-11 | Biorexis Pharmaceutical Corporation | Peptide yy modified transferrin fusion proteins |
| CA2606989A1 (en) * | 2005-04-29 | 2006-11-09 | Research Development Foundation | Vascular targeting of ocular neovascularization |
| WO2007087689A1 (en) | 2006-02-03 | 2007-08-09 | Crc For Asthma And Airways Ltd | A method of modulating cellular activity and agents for use therein |
| CN101070349B (zh) * | 2007-05-22 | 2010-10-13 | 山西康宝生物制品股份有限公司 | 具有选择性杀伤肿瘤新生血管内皮细胞作用的融合蛋白与应用 |
| CN101092452A (zh) * | 2007-05-23 | 2007-12-26 | 哈尔滨医科大学 | 肿瘤抑素抗血管生成小分子多肽、融合蛋白及两者制备方法 |
| WO2009086132A2 (en) * | 2007-12-20 | 2009-07-09 | University Of Southern California | Design of spacers to increase the expression of recombinant fusion proteins |
| AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
-
2012
- 2012-08-15 US US14/239,176 patent/US9290562B2/en active Active
- 2012-08-15 ES ES12824616.2T patent/ES2659161T3/es active Active
- 2012-08-15 PL PL12824616T patent/PL2744831T3/pl unknown
- 2012-08-15 CN CN201910156923.9A patent/CN110105453A/zh active Pending
- 2012-08-15 PT PT128246162T patent/PT2744831T/pt unknown
- 2012-08-15 WO PCT/US2012/051013 patent/WO2013025846A2/en not_active Ceased
- 2012-08-15 JP JP2014526189A patent/JP6073888B2/ja active Active
- 2012-08-15 CA CA2849015A patent/CA2849015C/en active Active
- 2012-08-15 TR TR2018/02686T patent/TR201802686T4/tr unknown
- 2012-08-15 DK DK12824616.2T patent/DK2744831T3/en active
- 2012-08-15 AU AU2012296588A patent/AU2012296588B2/en active Active
- 2012-08-15 CN CN201280051256.4A patent/CN103998470A/zh active Pending
- 2012-08-15 SI SI201231232T patent/SI2744831T1/en unknown
- 2012-08-15 EP EP12824616.2A patent/EP2744831B1/en active Active
- 2012-08-15 BR BR112014008680A patent/BR112014008680A2/pt unknown
-
2013
- 2013-07-22 NO NO13745268A patent/NO2820418T3/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2659161T3 (es) | 2018-03-14 |
| JP2014526890A (ja) | 2014-10-09 |
| PL2744831T3 (pl) | 2018-05-30 |
| TR201802686T4 (tr) | 2018-03-21 |
| US9290562B2 (en) | 2016-03-22 |
| NO2820418T3 (enExample) | 2018-05-05 |
| WO2013025846A2 (en) | 2013-02-21 |
| EP2744831A4 (en) | 2015-03-11 |
| CN103998470A (zh) | 2014-08-20 |
| PT2744831T (pt) | 2018-03-05 |
| AU2012296588A1 (en) | 2014-04-03 |
| BR112014008680A2 (pt) | 2017-06-13 |
| CA2849015A1 (en) | 2013-02-21 |
| DK2744831T3 (en) | 2018-03-05 |
| US20140179612A1 (en) | 2014-06-26 |
| AU2012296588B2 (en) | 2017-07-27 |
| JP6073888B2 (ja) | 2017-02-01 |
| CA2849015C (en) | 2017-08-08 |
| EP2744831A2 (en) | 2014-06-25 |
| WO2013025846A3 (en) | 2013-05-02 |
| EP2744831B1 (en) | 2017-12-06 |
| CN110105453A (zh) | 2019-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2732907T3 (es) | Procedimiento de expresión | |
| HRP20201031T1 (hr) | Anti-ctla-4 protutijela i postupci njihove upotrebe | |
| FI3835310T3 (fi) | Fibronektiinipohjaisia telinedomeeniproteiineja, jotka sitoutuvat myostatiiniin | |
| MX2014004214A (es) | Moleculas de acido ribonucleico policistronicas auto-replicantes recombinantes. | |
| JP2012522529A5 (enExample) | ||
| HRP20191409T1 (hr) | Postupci i sredstva za proizvodnju heterodimernih ig-sličnih molekula | |
| BR112013019975A2 (pt) | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" | |
| CY1119925T1 (el) | Aνti-cd40 αντισωματα, χρησεις και μεθοδοι | |
| HRP20250397T1 (hr) | Postupak i sastavi za staničnu imunoterapiju | |
| WO2013120012A3 (en) | Cdim binding proteins and uses thereof | |
| MX2020006065A (es) | Metodos y productos para la produccion y administracion de acido nucleico. | |
| JP2013135695A5 (enExample) | ||
| BR112012008142A2 (pt) | conjugados de peptídeo/ polietilenoglicol liga dos a dissulfeto para a transfecção de ácidos nucleicos | |
| AR094141A1 (es) | Composiciones y metodos para proteinas de accion prolongada | |
| HRP20240996T1 (hr) | Prefuzija rsv f proteina i njihova uporaba | |
| EA201200549A1 (ru) | Dll4-связывающие молекулы | |
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| MY162564A (en) | Modified binding proteins inhibiting the vegf-a receptor interaction | |
| BR112015014751A8 (pt) | anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos. | |
| MX2014007516A (es) | Procesos que utilizan vlps con capsides resistentes a hidrolasas. | |
| PE20170071A1 (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas | |
| HRP20190472T4 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| MX382822B (es) | Metodos y productos para transfeccion de celulas. | |
| BRPI1008145B8 (pt) | Proteína de ligação de antígeno biespecífica, método para preparar uma proteína de ligação de antígeno biespecífica, micro-organismo transgênico, composição farmacêutica e uso da proteína de ligação de antígeno biespecífica | |
| FI3461261T3 (fi) | Yksiketjuisen vaihtelevan fragmentin sisältäviä cd3:a sitovia proteiineja |